المؤلفون: Berkowitz, Gertrud S., Wetmur, James G., Birman-Deych, Elena, Obel, Josephine, Lapinski, Robert H., Godbold, James H., Holzman, Ian R., Wolff, Mary S.

المصدر: Environmental Health Perspectives, 2004 Mar 01. 112(3), 388-391.

URL الوصول: https://www.jstor.org/stable/3435665

المؤلفون: Carusone, Teresa Maria, Cardiero, Giovanna, Cerreta, Mariangela, Mandrich, Luigi, Moran, Oscar, Porzio, Elena, Catara, Giuliana, Lacerra, Giuseppina, Manco, Giuseppe

المصدر: Cell death and disease 11 (2020). doi:10.1038/s41419-020-2504-2
info:cnr-pdr/source/autori:Carusone, Teresa Maria and Cardiero, Giovanna and Cerreta, Mariangela and Mandrich, Luigi and Moran, Oscar and Porzio, Elena and Catara, Giuliana and Lacerra, Giuseppina and Manco, Giuseppe/titolo:WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2/doi:10.1038%2Fs41419-020-2504-2/rivista:Cell death and disease/anno:2020/pagina_da:/pagina_a:/intervallo_pagine:/volume:11
Cell Death & Disease
info:cnr-pdr/source/autori:Carusone, Teresa Maria; Cardiero, Giovanna; Cerreta, Mariangela; Mandrich, Luigi; Moran, Oscar; Porzio, Elena; Catara, Giuliana; Lacerra, Giuseppina; Manco, Giuseppe/titolo:WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2/doi:10.1038%2Fs41419-020-2504-2/rivista:Cell death and disease/anno:2020/pagina_da:/pagina_a:/intervallo_pagine:/volume:11
Cell Death and Disease, Vol 11, Iss 5, Pp 1-17 (2020)

مصطلحات موضوعية: Models, Molecular, Cancer Research, Transcription, Genetic, Ubiquitylation, Hydrolases, Operon, Cell Cycle Proteins, BINDING-PROTEINS, chemistry.chemical_compound, X-Ray Diffraction, Lactonase, Protein Isoforms, OXIDATIVE STRESS, biology, lcsh:Cytology, Chemistry, regulation, SMALL-ANGLE SCATTERING, SAXS, Baculoviral IAP Repeat-Containing 3 Protein, Ubiquitin ligase, Cell biology, FAMILY, PHOSPHOTRIESTERASE, RNA Splicing Factors, Gene isoform, Immunology, Homoserine, Models, Biological, Polymorphism, Single Nucleotide, Article, CLONING, Cellular and Molecular Neuroscience, Scattering, Small Angle, Humans, TUMOR 1-ASSOCIATING PROTEIN, structure, Amino Acid Sequence, Gene Silencing, RNA, Messenger, lcsh:QH573-671, Adenosine Diphosphate Ribose, Messenger RNA, IDENTIFICATION, STABILITY, Aryldialkylphosphatase, Ubiquitination, Wild type, Cell Biology, human PON2, PARAOXONASE GENE POLYMORPHISMS, Kinetics, Gene Expression Regulation, A549 Cells, Mutation testing, biology.protein, Peptides, Protein Processing, Post-Translational, HeLa Cells

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff23294abf1c461458e1eb9d2fe4f50a
http://www.cnr.it/prodotto/i/434359

المؤلفون: BAYINDIR, Hasan, GÜLEÇ CEYLAN, Gülay, NEŞELİOĞLU, Salim

المصدر: Volume: 15, Issue: 3 176-181
Harran Üniversitesi Tıp Fakültesi Dergisi

مصطلحات موضوعية: Alzheimer's disease,homocysteine,methylenetetrahydrofolate reductase,paraoxonase gene polymorphism, Alzheimer hastalığı,homosistein,metilentetrahidrofolat redüktaz,paraoksonaz gen polimorfizmi

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=tubitakulakb::264bade63e0ca10089cce1fbd94ac4bb
https://dergipark.org.tr/tr/pub/hutfd/issue/41021/461326

المؤلفون: Bunzou MATSUURA, Morikazu ONJI, Takenori SAKAI

المصدر: Internal Medicine. 1998, 37(7):581

المؤلفون: BAYINDIR, Hasan, GÜLEÇ CEYLAN, Gülay, NEŞELİOĞLU, Salim

المصدر: Volume: 15, Issue: 3 176-181 ; 1304-9623 ; 1309-4025 ; Harran Üniversitesi Tıp Fakültesi Dergisi

مصطلحات موضوعية: Alzheimer's disease,homocysteine,methylenetetrahydrofolate reductase,paraoxonase gene polymorphism, Alzheimer hastalığı,homosistein,metilentetrahidrofolat redüktaz,paraoksonaz gen polimorfizmi

وصف الملف: application/pdf

Relation: https://dergipark.org.tr/tr/download/article-file/594814; https://dergipark.org.tr/tr/pub/hutfd/issue/41021/461326

الاتاحة: https://dergipark.org.tr/tr/pub/hutfd/issue/41021/461326

المؤلفون: Emür, Pınar

المساهمون: Haspolat, Kenan, Dicle Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, TR157058, Emür, Pınar

مصطلحات موضوعية: Pediatri, Diyabetes mellitus, Paraoksonaz geni, Pediatrics, Paraoxonase gene

وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______3346::46c4f7c73278d8f0e732048186ba7cf6
https://hdl.handle.net/11468/1598

المصدر: Клінічна ендокринологія та ендокринна хірургія; № 2(43) (2013); 38-46
Clinical endocrinology and endocrine surgery; № 2(43) (2013); 38-46
Клиническая эндокринология и эндокринная хирургия; № 2(43) (2013); 38-46

مصطلحات موضوعية: сахарный диабет 2-го типа, полиморфизм гена параоксоназы, омега-3 полиненасыщенные жирные кислоты, type 2 diabetes mellitus, paraoxonase gene polymorphism, omega-3 polyunsaturated fatty acids

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=scientific_p::d4d08040d89ee4254dde799cd53747cf
http://jcees.endocenter.kiev.ua/article/view/77607

المؤلفون: Li, JP, Wang, XB, Huo, Y, Niu, TH, Chen, CZ, Zhu, GY, Huang, YM, Chen, DF, Xu, XP

المساهمون: Xu, XP (reprint author), Harvard Univ, Sch Publ Hlth, Program Populat Genet, 665 Huntington Ave, Boston, MA 02115 USA., Harvard Univ, Sch Publ Hlth, Program Populat Genet, Boston, MA 02115 USA., Childrens Mem Hosp, Mary Ann J Milburn Smith Child Hlth Res Program, Boston, MA USA., Childrens Mem Res Ctr, Boston, MA USA., Peking Univ, Affiliated Hosp 1, Dept Cardiol, Beijing 100871, Peoples R China., Peking Univ, Hlth Sci Ctr, Ctr EcoGenet & Reprod Hlth, Dept Genet & Cell Biol, Beijing 100871, Peoples R China., Harvard Univ, Sch Publ Hlth, Program Populat Genet, 665 Huntington Ave, Boston, MA 02115 USA.

المصدر: SCI

مصطلحات موضوعية: human paraoxonase 1 gene (PON1), polymorphism, myocardial infarction, diabetes mellitus, obesity, CORONARY-HEART-DISEASE, LOW-DENSITY-LIPOPROTEIN, HUMAN PARAOXONASE GENE, ARTERY-DISEASE, GLN-ARG192 POLYMORPHISM, INSULIN-RESISTANCE, OXIDATION, PARTICLES, HEALTHY, SUSCEPTIBILITY

Relation: GENETICS IN MEDICINE.2005,7,(1),58-63.; 994585; http://hdl.handle.net/20.500.11897/399712; WOS:000226374000010

الاتاحة: https://hdl.handle.net/20.500.11897/399712
https://doi.org/10.1097/01.GIM.0000151152.78092.CA

المؤلفون: Kakafika, A. I., Xenofontos, S., Tsimihodimos, V., Tambaki, A. P., Lourida, E. S., Kalaitzidis, R., Cariolou, M. A., Elisaf, M., Tselepis, A. D.

مصطلحات موضوعية: high density lipoprotein, platelet-activating factor acetylhydrolase, paraoxonase-1, pon1 polymorphisms, platelet-activating factor acetyllrydrolase polymorphisms, platelet-activating-factor, high-density-lipoprotein, coronary-heart-disease, independent risk-factor, factor-acetylhydrolase, oxidative modification, missense mutation, paraoxonase gene, artery disease, human-plasma

Relation: http://olympias.lib.uoi.gr/jspui/handle/123456789/9668

الاتاحة: http://olympias.lib.uoi.gr/jspui/handle/123456789/9668

المؤلفون: Xin Hong Yang, Jing Bai, Yan Yan Meng, Hui Zhou, Hua Fen Liu

المصدر: Asian Pacific Journal of Tropical Medicine. (7):544-547

مصطلحات موضوعية: Male, medicine.medical_specialty, Coronary Artery Disease, Transfection, Paraoxonase gene, Injections, law.invention, Random Allocation, law, Internal medicine, Hyperlipidemia, Epicardial adipose tissue, medicine, Animals, Gene, Triglycerides, Coronary atherosclerosis, Vascular tissue, Medicine(all), Analysis of Variance, biology, Aryldialkylphosphatase, Chemistry, Pericardial cavity, Paraoxonase, Genetic Therapy, General Medicine, medicine.disease, Cholesterol, Endocrinology, Recombinant DNA, biology.protein, Rabbits

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab538a98dc2a59463b8b5a48724c3816

المؤلفون: 江濬如, Chiang, Chun-Ju

المساهمون: 陳建仁, 臺灣大學：流行病學研究所

مصطلحات موضوعية: 阿滋海默症, 血管性失智症, 流行病學, 身體質量指數, 危險因子, 基因多型性, 瘦素受體基因, Paraoxonase基因, Vascular Dementia, Epidemiology, Body Mass Index, Risk Factors, Gene Polymorphisms, Leptin Receptor Gene, Paraoxonase Gene

وصف الملف: 2476263 bytes; application/pdf

Relation: 1. Plum F. Dementia: an approaching epidemic. Nature 1979;279:372-373. 2. Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004;292:2901-2908. 3. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004;63:1155-1162. 4. Edwardson J, Morris C. The genetics of Alzheimer’s disease. BMJ 1998;317:361-362. 5. Cataldo AM, Peterhoff CM, Schmidt SD, Terio NB, Duff K, Beard M, Mathews PM, Nixon RA. Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol 2004;63:821-830. 6. Tanzi RE. Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 2005;120:545-555. 7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th revised edition. Washington, DC 1994. 8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944. 9. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, and Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260. 10. O'Connor DW, Pollitt PA, Hyde JB, Fellows JL, Miller ND, Brook CPB, Reiss BB, Roth M. The prevalence of dementia a measured by the Cambridge Mental Disorder for the Elderly Examination. Acta Psychiatr Scand 1989;79:190-198. 11. Fratiglioni L, Grut M, Forsell Y, Viitanen M, Grafstrom M, Holmen K, Ericsson K, Backman L, Ahlbom A, Winblad B. Prevalence of Alzheimer's disease and other dementia in an elderly urban population: Relationship with age, sex, and education. Neurology 1991;41:1886-1892. 12. Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, D'Agostino RB, White LR. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study. Neurology 1992;42:115-119. 13 Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen T, Grobbee DE, Hofman A. Prevalence of Alzheimer’s disease and vascular dementia: association with education. the Rotterdam Study. BMJ 1995;310:970-973. 14. Andersen K, Lolk A, Nielsen H, Andersen J, Olsen C, Kragh-Sørensen P. Prevalence of very mild to severe dementia in Denmark. Acta Neurol Scand 1997;96:82-87. 15. Ueda K, Kawano H, Hasuo Y, Fujishima M. Prevalence and etiology of dementia in a Japanese community. Stroke 1992;23:798-803. 16. Yamada M¬, Sasaki H¬, Mimori Y¬, Kasagi F¬, Sudoh S¬, Ikeda J, Hosoda Y, Nakanura S, Kodama K. Prevalence and risks of dementia in the Japanese population: RERF's adult health study Hiroshima subjects. Radiation Effects Research Foundation. J Am Geriatr Soc 1999;47:189-195. 17. Zhang M, Katzman R, Salmon D, Jin H, Cai G, Wang Z, Qu G, Grant I, Yu E, Levy P, Klauber MR, Liu WT. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990;27:428-437. 18. Chiu HF, Lam LC, Chi I, Leung T, Li SW, Law WT, Chung DW, Fung HH, Kan PS, Lum CM, Ng J, Lau J. Prevalence of dementia in Chinese elderly in Hong Kong. Neurology 1998;50:1002-1009. 19. Liu CK. Dementia research in Taiwan. Acta Neurol Taiwan 2003;Suppl1:152-159. 20. Ritchie K¬, Lovestone S¬. The dementias. Lancet 2002;360:1759-1766. 21. Liu CK, Lai CL, Tai CT, Lin RT, Yen YY, Howng SL. Incidence and subtypes of dementia in southern Taiwan: impact of socio-demographic factors. Neurology 1998;50:1572-1579. 22. Essink-Bot ML¬, Pereria J¬, Packer C¬, Schwarzinger M¬, Burstrom K¬. Cross-national comparability of burden of disease estimates: the European Disability Weights Project. Bull. World Health Organ 2002;80:644-652. 23. Liu RT, Lai CL, Tai CT, Liu CK, Yen YY, Howng SL. Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. J Neurol Sci 1998;160:67-75. 24. Stern Y, Alexander GE, Prohovnik I, Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer’s disease. Ann Neurol 1992;32:371-375. 25. Elkins JS, O'Meara ES, Longstreth WT Jr, Carlson MC, Manolio TA, Johnston SC. Stroke risk factors and loss of high cognitive function. Neurology 2004;63:793-799. 26. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging 2000;21:57-62. 27. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Iivonen S, Hannermaa A, Tuomilehto J, Nissinen A, and Soininen S. Apolipoprotein E epsilon4 Allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer Disease. Ann Intern Med 2002;137:149-155. 28. Kivipelto M, Ngandu T, Fratiglioni L,Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer’s disease. Arch Neurol 2005;62:1556-1560. 29. Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 2003;51:410-414. 30. Schnaider BM, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, Sverdlick A, Davidson M. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004;63:1902-1907. 31. Hebert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF. Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 2000;31:1487-1493. 32. Barnes DE, Yaffe K, Satariano WA, Tager IB. A longitudinal study of cardiorespiratory fitness and cognitive function in healthy older adults. J Am Geriatr Soc 2003;51:459-465. 33. Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 2004;63:228-233. 34. Wolf H, Hensel A, Arendt T, Kivipelto M, Winblad B, Gertz HJ. Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol 2004;56:745-749. 35. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61:705-714. 36. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483. 37. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology 2004;62:1573-1579. 38. Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, and Sacco RL. Total homocysteine and cognition in a tri-ethnic cohort: The Northern Manhattan Study. Neurology 2004;63:254-260. 39. Whitmer RA, Sidney S, Selby J, Claiborne Johnston S, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-281. 40. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-643. 41. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163:1524-1528. 42. Rosengren A, Skoog I, Gustafson D, Wilhelmsen L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 2005;165:321-326. 43. Wang SY. Weight loss and metabolic changes in dementia. J Nutr Health Aging 2002;6:201-205. 44. Baumgartner RN, Heymsfield SB, Roche AF. Human body composition and the epidemiology of chronic disease. Obes Res 1995;3:73-95. 45. Cronin-Stubbs D, Beckett LA, Scherr PA, Field TS, Chown MJ, Pilgrim DM, Bennett DA, Evans DA. Weight loss in people with Alzheimer's disease: a prospective population based analysis. BMJ 1997;314:178-179. 46. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005;65:892-897. 47. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry Jr CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005;330:1360-1363. 48. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-1631. 49. Wolozin B, Kellman W, Ruisseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443. 50. Li G, Higdon R, Kukull WA, Peskind E, van Valen Moore K, Tsuang D, van Belle G, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004;63:1624-1628. 51. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol 2005;62:1047-1051. 52. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-174. 53. Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizarry MC, Hyman BT. Nonsteroidal anti-inflammatory drugs lower AB42 and change presenilin 1 conformation. Nat Med 2004;10:1065-1066. 54. In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MMB, Stricker Bruno HC. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521. 55. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner CS. Reduced incidence of AD with NSAID but not H2 receptor antagonist: The Cache County Study. Neurology 2002;59:880-886. 56. Potyk D. Treatments for Alzheimer disease. South Med J 2005;98:628-635. 57. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, Guralnik JM, Breitner JCS. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology 2000;55:1158-1166. 58.Jordan BD, Pelkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 1997;278:136-140. 59. Ilonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, Clark RS, Marion DW, Wisniewski SR, Dekosky ST. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 2004;190:192-203. 60. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, Brayne C, Copeland JRM, Dartigues JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A. Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses. Neurology 1999;52:78-84. 61. Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer’s disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445-453. 62. Bartecchi CE, MacKenzie TD, Schrier RW. The human costs of tobacco use (1). N Engl J Med 1994;330:907-912. 63. Shinton R, Beevers G. Mata-analysis of the relation between cigarette smoking and stroke. BMJ 1989;298:789-794. 64. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994;13:131-144. 65. Van Duijn C, Hofman A. Relation between nicotine intake and Alzheimer´s disease. BMJ 1991;302:1491-1494. 66. Graves AB, Van Duijn CM, Chandra V, Fratiglioni L, Heyman A, Jorm AF. Alcohol and tobacco consumption as risk factor for Alzheimer´s disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20:S48-S57. 67. Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002;97:15-28. 68. Hebert LE, Scherr PA, Beckett LA, Funkestein HH, Alnert MS, Chown MJ. Relation of smoking and alcohol consumption to incident Alzheimer’s disease. Am J Epidemiol 1992;135:347-355. 69. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, van Broeckhoven C, van Duijn CM, Breteler MMB. Smoking and risk of dementia and Alzheimer´s disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-1843. 70. Ott A, Andersen K, Dewey ME, Letenneur L, Brayne C, Copeland JRM, Dartigues JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A, Launer LJ. Effect of smoking on global cognitive function in nondemented elderly. Neurology 2004;62:920-924. 71. Huang W, Qiu C, Winblad B, Fratiglioni L. Alcohol consumption and incidence of dementia in a community sample aged 75 years and older. J Clin Epidemiol 2002;55:959-964. 72. Ruitenberg A, van Swieten JC, Witteman JC, Mehta KM, van Duijn CM, Hofman A, Breteler MM. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002;359:281-286. 73. Mukamal KJ, Kuller LH, Fitzpatrick AL, Longstreth WT Jr, Mittleman MA, Siscovick DS. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003;289:1405-1413. 74. Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 2002;59:1313-1319. 75. Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med 2005;352:245-253. 76. Fujishima M, Kiyohara Y. Incidence and risk factors of dementia in a defined elderly Japanese population: the Hisayama study. Ann NY Acad Sci 2002;977:1-8. 77. Dufouil C, Tzourio C, Brayne C, Berr C, Amouyel P, Alperovitch A. Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers. Epidemiology 2000;11:280-284. 78. Wilson RS, Schneider JA, Bienias JL, Arnold SE, Evans DA, Bennett DA. Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. Neurology 2003;61:1102-1107. 79. Andersen K, Lolk A, Kragh-Sørensen P, Petersen NE, Green A. Depression and the risk of Alzheimer disease. Epidemiology 2005;16:233-238. 80. MOdrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004;61:1290-1293. 81. Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH. Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol 2005;57:381-387. 82. Morris JC. Dementia Update 2005. Alzheimer Dis Assoc Disord 2005;19:100-117. 83. Shastry BS, Giblin FJ. Genes and susceptible loci of Alzheimer’s disease. Brain Res Bull 1999;48:121-127. 84. Tanzi RE, Bertram L. Twenty Years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 2005;120:545-555. 85. Panza F, D’Introno A, Colacicco M, Basile AM, Capurso C, Kehoe PG, Capurso A, Solfrizzi V. Vascular risk and genetics of sporadic late-onset Alzheimer’s disease. J Neural Transm 2004;111:69-89. 86. Zuliani G, Ble A, Zanca R, Munari MR, Zurlo A, Vavalle C, Atti AR, Fellin R. Genetic polymorphisms in older subjects with vascular or Alzheimer’s dementia. Acta Neuro Scand 2001;103:304-308. 87. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630. 88. Mahley RW, Rall Jr SC. Apolipoprotein E: far more than a lipid transport protein. Ann Rev Genomics Hum Genet 2000;1:507-537. 89. Corder EH, Saunders AM, Strittmatter WJ, chmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type ε4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921-923. 90. Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer’s disease carrying apolipoprotein ε4 allele. J Neurosci 1997;17:516-529. 91. Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ. The apolipoprotein E epsilon-4 allele is associate d with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 1996;47:190-196. 92. Qiu Z, Strickland DK, Hyman BT, Rebeck GW. Alpha-2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem 1999;73:1393-1398. 93. Alvarez V, Alvarez R, Lahoz CH, Martinez C, Pena J, Guisasola LM, Salas-Puig J, Moris G, Uria D, Menes BB, Ribacoba R, Vidal JA, Sanchez JM, Coto E. Association between an alpha-2-macroglobulin DNA polymorphism and late-onset Alzheimer’s disease. Biochem Biophys Res Commun 1999;264:48-50. 94. Sodeyama N, Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E, Mizusawa H. Alpha-2-macroglobulin polymorphism is not associated with AD or AD-type neuropathology in the Japanese. Neurology 2000;54:443-446. 95. Liao A, Nitsch RM, Greenberg SM, Finckh U, Blacker D, Albert M, Rebeck GW, Gomez-Isla T, Clatworthy A, Binetti G, Hock C, Mueller-Thomsen T, Mann U, Zuchowski K, Beisiegel U, Staehelin H, Growdon JH, Tanzi RE, Hyman BT. Genetic association of an alpha2-macroglobulin (Val1000Ile) polymorphism and Alzheimer’s disease. Hum Mol Genet 1998;7:1953-1956. 96. Wang X, Luedecking EK, Minster RL, Ganguli M, DeKosky ST, Kamboh MI. Lack of association between alpha-2-macroglobulin polymorphisms and Alzheimer’s disease. Hum Genet 2001;108:105-108. 97. Myklebost O, Arheden K, Rogne S, Geurts van Kessel A, Mandahl N, Herz J, Stanley K, Heim S, Mitelman F. The gene for the human putative apoE receptor is on chromosome 12 in the segment q13–14. Genomics 1989;5:65-69. 98. Kang DE, SaitohT, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer’s disease. Neurology 1997;49:56-61. 99. Hollenbach E, Ackermann S, Hyman BT, Rebeck GW. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer’s disease. Neurology 1998;50:1905-1907. 100. Pritchard A, Harris J, Pritchard CW, St Clair D, Lemmon H, Lambert JC, Chartier-Harlin MC, Hayes A, Thaker U, Iwastsubo T, Mann DM, Lendon C. Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease. Neurosci Lett 2005;382:221-226. 101. Luedecking-Zimmer E, Dekosky ST, Nebes R, Kamboh MI. Association of the 3' UTR transcription factor LBP-1c/CP2/LSF polymorphism with late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2003;117:114-117. 102. Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, Ueki A, Nanko S, Tanaka H, Takahashi H. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer’s disease. Nat Genet 1995;11:207-209. 103. Yamanaka H, Kamimura K, Tanahashi H, Takahashi K, Asada T, Tabira T. Genetic risk factors in Japanese Alzheimer’s disease patients: alpha1-ACT, VLDLR, and ApoE. Neurobiol Aging 1998;19:43-46. 104. Okuizumi K, Onodera O, Seki K, Tanaka H, Namba Y, Ikeda K, Saunders AM, Pericak-Vance MA. Roses AD, Tsuji S. Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer’s disease. Ann Neurol 1996;40:251-254. 105. Helbecque N, Berr C, Cottel D, Fromentin-David I, Sazdovitch V, Ricolfi F, Ducimetiere P, Menza D, Amouyel P. VLDL receptor polymorphism, cognitive impaitment, and dementia. Neurology 2001;56:1183-1188. 106. McIlroy SP, Vahidassr MD, Savage DA, Patterson CC, Lawson JT, Passmore AP. Risk of Alzheimer’s disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland. Am J Med Genet 1999;88:140-144. 107. Chen L, Baum L, Ng HK, Chan YS, Mak YT, Woo J, Chiu H, Pang CP. No association detected between very-low-density lipoprotein receptor (VLDL-R) and late-onset Alzheimer’s disease in Hong Kong Chinese. Neurosci Lett 1998;24:33-36. 108. Fallin D, Gauntlett AC, Scibelli P, Cai X, Duara R, Gold M, Crawford F, Mullan M. No association between the very low density lipoprotein receptor gene and late-onset Alzheimer’s disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol 1997;14:299-305. 109. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000;20:1657-1665. 110. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM. Susceptibility locus for Alzheimer’s disease on chromosome 10. Science 2000;290:2304-2305. 111. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K. Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q. Science 2000;290:2302-2303. 112. Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, Compton D, Spurlock G, Turic D, Hoogendoorn B. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer’s disease. Hum Genet 2001;109:646-652. 113. Boussaha M, Hannequin D, Verpillat P, Brice A, Frebourg T, Campion D. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer’s disease. Neurosci Lett 2000;329:121-123. 114. Bian L, Yang JD, Guo TW, Sun Y, Duan SW, Chen WY, Pan YX, Feng G.Y, He L. Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese. Neurology 2004;63:241-245. 115. Sakai A, Ujike H, Nakata K, Takehisa Y, Imamura T, Uchida N, Kanzaki A, Yamamoto M, Fujisawa Y, Okumura K, Kuroda S. No association between the insulin degrading enzyme gene and Alzheimer’s disease in a Japanese population. Am J Med Genet 2004;125:87-91. 116. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC. Results of a high-resolution genome screen of 437 Alzheimer’s disease families. Hum Mol Genet 2003;12:23-32. 117. Nowotny P, Kwon JM, Chakraverty S, Nowotny V, Morris JC, Goate AM. Association studies using novel polymorphisms in BACE1 and BACE2. NeuroReport 2001;13:1799-1802. 118. Kan R, Wang B, Zhang C, Jin F, Yang Z, Ji S, Lu Z, Zheng C, Wang L. Genetic association of BACE1 gene polymorphism C786G with late-onset Alzheimer's disease in Chinese. J Mol Neurosci 2005;25:127-131. 119. Liu HC, Leu SJ, Chang JG, Sung SM, Hsu WC, Lee LS, Hu CJ. The association of beta-site APP cleaving enzyme (BACE) C786G polymorphism with Alzheimer's disease. Brain Res 2003;961:88-91. 120. Bertram L, Tanzi RE. Alzheimer's disease: one disorder, too many genes? Hum Mol Genet 2004;13:R135-41. 121. Collins JS, Perry RT, Watson B Jr, Harrell LE, Acton RT, Blacker D, Albert MS, Tanzi RE, Bassett SS, McInnis MG, Cambell RD, Go RC. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. Am J Med Genet 2000;96:823-830. 122. McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC, McIlroy SP, Passmore AP. Association between polymorphism in regulatory region of gene encoding tumor necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 2001;357:436-439. 123. Laws SM, Perneczky R, Wagenpfeil S, Muller U, Forstl H, Martins RN, Kurz A, Riemenschneider M. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat 2005;26:29-35. 124. Terreni L, Fogliarino S, Quadri P, Ruggieri RM, Piccoli F, Tettamanti M, Lucca U, Forloni G. Tumor necrosis factor alpha polymorphism C-850T is not associated with Alzheimer's disease and vascular dementia in an Italian population. Neurosci Lett 2003;344:135-137. 125. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K. Polymorphism of the 5’flanking region of the human necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998;51:605-612. 126. Ma SL, Tang LS, Lam CW, Chiu FK. Association between tumor necrosis factor-α promoter polymorphism and Alzheimer’s disease. Neurology 2004;62:307-309. 127. Cheng CY, Hong CJ, Liu HC, Liu TY, Tsai SJ. Study of the association between Alzheimer’s disease and angiotensin-converting enzyme gene polymorphism using DNA from lymphocytes. Eur Neurol 2002;47:26-29. 128. Elkins JS, Douglas VC, Johnston SC. Alzheimer’s disease risk and genetic variation in ACE: a meta-analysis. Neurology 2004;62:363-368. 129. Kolsch H, Jessen F, Freymann N, Keros M, Hentschel F, Marier W, Heun R. ACE I/D polymorphism is a risk factor pf Alzheimer’s disease but not of vascular dementia. Neurosci Lett 2005;377;37-39. 130. Lendon CL, Thaker U, Harris JM, McDonagh AM, Lambert JC, Chartier-Harlin MC, Iwatsubo T, Pickering-Brown SM, Mann DM. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer’s disease. Neurosci Lett 2002;328:314-318. 131. Seshadri S, Beiser A, Selhub J, Jacques RF, Rosenberg IH, D’Agostino RB, Wilson PWF, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. New Engl J Med 2002;346:476-483. 132. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews R, Boers GHJ, Heijer MD, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113. 133. Nishiyama M, Kato Y, Hashimoto M, Yukawa S, Omori K. Apolipoprotein E, methylenetetrahydrofolatereductase (MTHFR) mutation and the risk of senile dementia: an epidemiological study using the polymerase chain reaction (PCR) method. J Epidemiol 2000;10:163-172. 134. Pollak RD, Pollak A, Idelson M, Bejarano-Achache I, Doron D, Blumenfeld A. The C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and vascular dementia. J Am Geriatr Soc 2000;48:664-668 135. Brunelli T, Bagnoli S, Giusti B, Nacmias B, Pepe G, Sorbi S, Abbate R. The C677T methylenetetrahydrofolate reductase mutation is not associated with Alzheimer’s disease. Neurosci Lett 2001;315:103-105. 136. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351-2356. 137. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih D, Fonarow GC. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998;9:319-324. 138. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57-60. 139. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I. Serum paraoxonase activity changes in patients with Alzheimer’s disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002;252:63-67. 140. Dantoine TF, Debord J, Merle L, Lacroix-Ramiandrisoa H, Bourzeix L, Charmes JP. Paraoxonase 1 activity: a new vascular marker of dementia? Ann NY Acad Sci 2002;977:96-101. 141. Pola R, Gaetani E, Flex A, Gerardino L, Aloi F, Flore R, Serricchio M, Pola P, Bernabei R. Lack of association between Alzheimer’s disease and Gln-Arg 192 Q/R polymorphism of the PON1 gene in an Italian population. Dement Geriatr Cogn Disord 2003;15:88-91. 142. Wang PN, Liu HC, Liu TY, Chu A, Hong CJ, Lin KN. Estrogen-metabolizing gene COMT polymorphism synergistic APOE ε4 allele increases the risk of Alzheimer disease. Dement Geriatr Cogn Disord 2005;19:120-125. 143. Norbury R, Cutter WJ, Compton J, Robertson DM, Craig M, Whitehead M, Murphy DG. The neuroprotective effects of estrogen on the aging brain. Exp Gerontol 2003;38:109-117. 144. Borroni B, Agosti C, Archetti S, Costanzi C, Bonomi S, Ghianda D, Lenzi GL, Caimi L, Di Luca M, Padovani A. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neurosci Lett 2004;370:127-129. 145. Wang PN, Liu HC, Liu TY, Chu A, Hong CJ, Lin KN, Chi CW. Estrogen-metabolizing gene COMT polymorphism synergistic APOE epsilon4 allele increases the risk of Alzheimer disease. Dement Geriatr Cogn Disord 2005;19:120-5. 146. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432. 147. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O’Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;87:903-908. 148. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998;18:213-215. 149. Kivipelto M, Ngandu T, Fratiglioni L,Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. Obesity and vascualr risk factors at midlife and the risk of dementia and Alzheimer’s disease. Arch Neurol 2005;62:1556-1560. 150. Power DA, Noel J, Collins R, O'Niell D. Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement Geriatr Cogn Disord 2001;12:167-170. 151. Fewlass DC, Noboa K, Pi-Sunyer X, Johnston JM, Yan SD, Tezapsidis N. Obesity-related leptin regulates Alzheimer's Aβ. FASEB J 2004;18:1870-1878. 152. Hu CJ, Sung SM, Liu HC, Hsu WC, Lee LS, Lee CC, Tsai CH, Chang JG. Genetic risk factors of sporadic Alzheimer’s disease among Chinese in Taiwan. J Neurol Sci 2000;181:127-131. 153. Huang HM, KuoYM, Ou HC, Lin CC, Chuo LJ. Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population. J Neural Transm 2002;109:1415-1421. 154. Chen CJ, Yu MW, Wang CJ, Huang HY, Lin WC. Multiple risk factors of hepatocellular carcinoma: A cohort study of 13737 male adults in Taiwan. J Gastroenterol Hepatol 1993;8:S83-S87. 155. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level. JAMA 2006;295:65-73. 156. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgens J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229. 157. Qin Z, Niu T, Liu J. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002;71:1242-1247. 158. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989. 159. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction. Am J Hum Genet 2003;73:1162-1169. 160. Gauderman WJ, Morrison JM. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies, 2006. http://hydra.usc.edu/gxe. 161. Elias MF, Elias PK, Sullivan LM, Wolf PA, D’Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J obes 2003;27:260-268. 162. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-2242. 163. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-495. 164. Farr SA, Banks WA, Morley JE. Effects of leptin on memory processing. Peptides 2006;27:1420-1425. 165. Gu D, He J, Duan X, Reynolds K, Wu X, Chen J, Huang G, Chen CS, Whelton PK. Body weight and mortality among men and women in China. JAMA 2006;295:779-783. 166. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, Ross GW, Havlik RJ, Launer LJ. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American Elderly Men: the Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000;20:2255-2260. 167. Chen H, Vlahos R, Bozinovski S, Jones J, Anderson GP, Morris MJ. Effect of short-term cigarette smoke exposure in body weight, appetite and brain neuropeptide Y in mice. Neuropsychopharmacology 2005;30:713-719. 168. Noale M, Maggi S, Minicuci N, Marzari C, Destro C, Farchi G, Scafato E, Baldereschi M, Di Carlo A, Crepaldi G. Dementia and disability: impact on mortality. The Italian Longitudinal Study of Aging. Dement Geriatr Cogn Disord 2003;16:7-14. 169. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of Diabetes Diagnosis in Health Insurance Claims Data in Taiwan. J Formos Med Assoc 2005;104:157-163. 170. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, Van Duijn CM. Effect of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer’s disease. a meta-analysis. JAMA 1997;278:1349-1356. 171. Edland SD, Wavrant-De Vriese F, Compton D, Smith GE, Ivnik R, Boeve BF, Tangalos EG, Petersen RC. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer’s disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett 2003;345:21-24. 172. Helbecque N, Amouyel P. Very low density lipoprotein receptor in Alzheimer disease. Microsc Res Tech 2000;50:273-277. 173. Arlt S, Beisiegel U, Kontush A. Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr Opin Lipidol 2002;13:289-294. 174. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 1998;252:711-715. 175. Scacchi R, Gambina G, Martini MC, Broggio E, Vilardo T, Corbo RM. Different pattern of association of paraoxonase Gln192Arg polymorphism with sporadic late-onset Alzheimer's disease and coronary artery disease. Neurosci Lett 2003;339:17-20. 176. He XM, Zhang ZX, Zhang JW, Zhou YT, Tang MN, Wu CB, Hong Z. Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chin Med J 2006;119:1204-1209. 177. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. Effect of COMT Val108/158MET genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001;98:6917-6922. 178. de Frias CM, Annerbrink K, Westberg L, Eriksson E, Adolfsson R, Nilsson LG. Catechol-O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. J Cogn Neurosci 2005;17:1018-1025. 179. Worda C, Sator MO, Schneeberger C, Jantschev T, Ferlitsch K, Huber JC. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum Reprod 2003;18:262-266. 180. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5. 181. Funahashi H, Yada T, Suzuki R, Shioda S. Distribution, function, and properties of leptin receptors in the brain. Int Rev Cytol 2003;224:1-27.; en-US; http://ntur.lib.ntu.edu.tw/handle/246246/56185; http://ntur.lib.ntu.edu.tw/bitstream/246246/56185/1/ntu-96-F89842016-1.pdf

الاتاحة: http://ntur.lib.ntu.edu.tw/handle/246246/56185
http://ntur.lib.ntu.edu.tw/bitstream/246246/56185/1/ntu-96-F89842016-1.pdf

Additional Titles: Экспрессивность реабелитирующих эффектов омега-3 полененасыщенных жирных кислот у больных сахарным диабетом 2-го типа с полиморфными вариантами гена параоксоназы
Експресивність реабілітуючих ефектів омега-3 поліненасичених жирних кислот у хворих на цукровий діабет 2-го типу з поліморфними варіантами гена параоксонази

المؤلفون: Горшунська, М. Ю.; Харківська медична академія післядипломної освіти, Караченцев, Ю. І.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Кравчун, Н. О.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Йенсен, Е.; Національний інститут охорони здоровʼя та довкілля, Білтховен, Атраментова, Л. О.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Гладких, О. І.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Красова, Н. С.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Лещенко, Ж. А.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Тижненко, Т. В.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Опалейко, Ю. А.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Почерняєв, А. К.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків, Полторак, В. В.; ДУ "Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України", Харків

المصدر: Clinical Endocrinology and Endocrine Surgery; № 2(43) (2013); 38-46; Clinical Endocrinology and Endocrine Surgery. Клиническая эндокринология и эндокринная хирургия; Clinical Endocrinology and Endocrine Surgery. Клінічна ендокринологія та ендокринна хірургія; 2519-2582; 1818-1384

مصطلحات الفهرس: type 2 diabetes mellitus, paraoxonase gene polymorphism, omega-3 polyunsaturated fatty acids, сахарный диабет 2-го типа, полиморфизм гена параоксоназы, омега-3 полиненасыщенные жирные кислоты, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion

URL: http://jcees.endocenter.kiev.ua/article/view/77607
http://jcees.endocenter.kiev.ua/article/view/77607/73351
http://jcees.endocenter.kiev.ua/article/view/77607/73351